How have IMNN and XBIO total returns compared?

Over the past 10 years, IMNN delivered -55.17% and XBIO delivered -41.64% annualized total return. Past performance doesn't predict future results.

Imunon, Inc. (IMNN) vs Xenetic Biosciences, Inc. (XBIO)

A side-by-side comparison of Imunon, Inc. and Xenetic Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IMNN

Imunon, Inc.

$5M

$1.21HealthcareDelayed quote: Oct 6, 2026, 2:47 PM EDT

XBIO

Xenetic Biosciences, Inc.

$5M

$2.16HealthcareDelayed quote: Oct 6, 2026, 2:43 PM EDT

Total return — IMNN vs XBIO

growth of $100 · dividends reinvested · last 10y

IMNN -100.0% (-55.2%/yr)XBIO -99.6% (-42.3%/yr)XBIO compounded faster over this window

Log scale — wide-divergence pair

IMNN XBIO

IMNN vs XBIO: by the numbers

•IMNN is the larger company ($5M vs $5M market cap).
•Both run net losses; IMNN's is the smaller (0.00% vs -75.90% net margin).

Metrics side by side

Valuation

Metric	IMNN	XBIO
P/S ratio	N/A	1.51
P/B ratio	1.21	0.81

Profitability

Metric	IMNN	XBIO
Gross margin	0.00%	100.00%
Operating margin	0.00%	-95.23%
Net margin	0.00%	-75.90%
ROE	-351.30%	-40.76%
ROIC	-126.69%	-43.50%

Growth (annualized)

Metric	IMNN	XBIO
Revenue CAGR (5Y)	N/A	34.31%
Total return CAGR (5Y)	-63.83%	-34.54%

Frequently asked

How have IMNN and XBIO total returns compared?: Over the past 10 years, IMNN delivered -55.17% and XBIO delivered -41.64% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IMNN analysis Full XBIO analysis Interactive comparison tool

Dig into the metrics

Imunon ROE Xenetic Biosciences ROE Imunon operating margin Xenetic Biosciences operating margin Imunon revenue growth Xenetic Biosciences revenue growth Imunon free cash flow Xenetic Biosciences free cash flow

Imunon & Xenetic Biosciences appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.